Cephalosporins and Beta-Lactamase Inhibitor Combinations

Correct Answer

B — Cefazolin

Rationale

Cefazolin is a first-generation cephalosporin, the workhorse agent for surgical prophylaxis and methicillin-susceptible Staphylococcus aureus infections in penicillin-intolerant patients. Ceftriaxone is third-generation. Cefepime is fourth-generation. Cefoxitin is a second-generation cephamycin.

Correct Answer

D — Ceftriaxone

Rationale

Ceftriaxone is a third-generation cephalosporin — the most clinically important agent in its generation, with once-daily dosing, excellent cerebrospinal fluid penetration, and broad gram-negative coverage. Cefazolin is first-generation. Cefepime is fourth-generation. Ceftaroline is fifth-generation.

Correct Answer

A — Cefepime

Rationale

Cefepime is the principal fourth-generation cephalosporin. It covers Pseudomonas aeruginosa, has enhanced stability against chromosomal AmpC enzymes, and retains gram-positive activity. Cefazolin is first-generation. Ceftriaxone is third-generation. Ceftaroline is fifth-generation.

Correct Answer

C — Ceftaroline

Rationale

Ceftaroline is a fifth-generation cephalosporin and is unique as the only beta-lactam antibiotic with approved activity against methicillin-resistant Staphylococcus aureus. Cefoxitin is a second-generation cephamycin. Cefepime is fourth-generation. Ceftriaxone is third-generation.

Correct Answer

B — Amoxicillin-clavulanate

Rationale

Amoxicillin-clavulanate pairs an aminopenicillin (amoxicillin) with clavulanic acid, a classical beta-lactamase inhibitor active against Class A enzymes. It is the standard oral broad-spectrum combination for outpatient infections. Piperacillin-tazobactam pairs an extended-spectrum penicillin with tazobactam, also a classical inhibitor but not an aminopenicillin combination. Ceftazidime-avibactam pairs a cephalosporin with avibactam, a novel inhibitor. Ampicillin-sulbactam is an aminopenicillin-inhibitor combination but sulbactam is the partner, not clavulanic acid.

Correct Answer

A — Ceftazidime-avibactam

Rationale

Ceftazidime-avibactam pairs a third-generation cephalosporin (ceftazidime) with avibactam, a novel non-beta-lactam beta-lactamase inhibitor that extends activity to Class A, Class C, and some Class D enzymes — including carbapenemases such as Klebsiella pneumoniae carbapenemase. The other three options all pair penicillins with classical inhibitors (clavulanic acid, tazobactam, or sulbactam) that act only against Class A enzymes.

Correct Answer

C — Ceftaroline has sufficient structural affinity for penicillin-binding protein 2a to inactivate it despite its low-affinity active site

Rationale

Methicillin-resistant Staphylococcus aureus resistance to beta-lactams is mediated by penicillin-binding protein 2a, an altered transpeptidase with an active site that has extremely low affinity for conventional beta-lactams. Ceftaroline is engineered with a side chain that achieves high enough binding affinity for penicillin-binding protein 2a to inactivate it despite this structural barrier, blocking cell wall synthesis in methicillin-resistant Staphylococcus aureus. No inhibitor partner is involved — ceftaroline is used as a single agent. Gene suppression and membrane lipophilicity are not the mechanism.

Correct Answer

A — First-generation gram-positive and limited gram-negative coverage matches typical surgical site pathogen exposure, and its 7-position side chain is structurally unrelated to penicillin side chains, minimizing cross-reactivity risk

Rationale

Surgical prophylaxis targets the organisms most likely to cause wound infections — predominantly gram-positive skin flora such as Staphylococcus aureus and Staphylococcus epidermidis, with limited gram-negative concern in most clean procedures. Cefazolin's first-generation spectrum covers this niche precisely. Its additional advantage is structural: the 7-position side chain of cefazolin is unrelated to any penicillin side chain, making it the cephalosporin with the lowest risk of cross-reactivity in penicillin-allergic patients and allowing its use in most patients with a penicillin allergy history after appropriate risk stratification. Cefazolin does not cover Pseudomonas or anaerobes, and it does not have an unusually long half-life nor biliary elimination.

Correct Answer

D — Ceftriaxone undergoes dual elimination — approximately 40% biliary and the remainder renal — so impaired renal function does not require dose adjustment

Rationale

Ceftriaxone is the major cephalosporin exception to predominantly renal elimination. Approximately 40% of the drug is eliminated by biliary secretion as unchanged drug, with the remainder cleared renally. This dual pathway means that impaired renal function does not cause meaningful drug accumulation, and dose adjustment is not required in renal impairment — making ceftriaxone the preferred agent for gram-negative bacteremia in patients with acute kidney injury. Most other cephalosporins are predominantly renally eliminated and require dose reduction in renal impairment. Ceftriaxone is not eliminated entirely hepatically, and its half-life of approximately 8 hours is the longest of the third-generation agents, not the shortest.

Correct Answer

B — They cannot inhibit Class B metallo-beta-lactamases or Class C AmpC enzymes

Rationale

Classical beta-lactamase inhibitors — clavulanic acid, sulbactam, and tazobactam — are irreversible inhibitors of Class A serine beta-lactamases, including extended-spectrum beta-lactamases and Klebsiella pneumoniae carbapenemase. They have no activity against Class B metallo-beta-lactamases (which use zinc rather than serine at the active site) or Class C AmpC enzymes (chromosomally encoded in organisms like Enterobacter and Pseudomonas). This mechanistic gap is clinically critical: organisms producing New Delhi metallo-beta-lactamase or other metallo-beta-lactamases are not covered by any classical inhibitor combination. Novel inhibitors such as avibactam extend coverage to include Class C and some Class D enzymes, but also not Class B.

Correct Answer

B — Avibactam cannot inhibit metallo-beta-lactamases, which use zinc at their active site rather than the serine residue targeted by avibactam

Rationale

Avibactam extends inhibitor coverage to a broader range of beta-lactamase enzymes than classical inhibitors, but it shares one critical gap with them: neither avibactam nor classical inhibitors can inhibit metallo-beta-lactamases. These enzymes use zinc at their active site rather than the serine residue that avibactam targets, making them structurally inaccessible to avibactam. This is the clinically critical gap that determines treatment failure when organisms produce metallo-beta-lactamases despite apparent susceptibility to ceftazidime-avibactam on in vitro testing. Avibactam is active against organisms producing serine-based beta-lactamases including carbapenemases of that type, and it is paired with ceftazidime, a cephalosporin — not a penicillin.

Correct Answer

A — Cephalosporins covalently inactivate penicillin-binding proteins, blocking peptidoglycan cross-linking; as autolysins continue degrading existing cell wall, the organism undergoes progressive structural failure and lysis

Rationale

Cephalosporins, like all beta-lactam antibiotics, achieve bactericidal activity through covalent inactivation of penicillin-binding proteins — the transpeptidase enzymes that cross-link the peptidoglycan strands of the bacterial cell wall. With cross-linking blocked and autolytic enzymes continuing to degrade existing peptidoglycan, the cell wall progressively weakens until osmotic stress causes bactericidal lysis. This mechanism is inherently lethal rather than merely growth-inhibiting, which is why beta-lactams are classified as bactericidal. The bactericidal effect is concentration-independent above the minimum inhibitory concentration — increasing peak concentration does not increase killing rate, which is why beta-lactams are time-dependent killers. Ribonucleic acid synthesis inhibition, membrane disruption, and dose-threshold bactericidal activity are not the mechanisms of cephalosporins.

Correct Answer

D — Cross-reactivity is determined primarily by structural similarity of the 7-position side chain of the cephalosporin to the corresponding side chain of the penicillin causing the original reaction

Rationale

The historically cited 10% cross-reactivity rate between penicillins and cephalosporins is not supported by current immunologic and clinical challenge data. True cross-reactivity is mediated by shared side-chain structures at the 7-position of the cephalosporin (equivalent to the 6-position in penicillins), not by the shared beta-lactam ring. Cephalosporins with side chains structurally unrelated to any penicillin carry cross-reactivity rates of approximately 1 to 2%. Cefazolin has the lowest risk because its 7-position side chain bears no structural resemblance to any penicillin side chain. Cephalosporins that share a side chain with amoxicillin — such as cefadroxil — carry meaningfully higher risk in patients with documented amoxicillin allergy.

Correct Answer

B — Cephamycins add anaerobic coverage including Bacteroides fragilis, making them useful for intra-abdominal and gynecologic infections

Rationale

Cephamycins — cefoxitin and cefotetan — are classified as second-generation cephalosporins but form a distinct subgroup because of their anaerobic coverage, particularly against Bacteroides fragilis. This property sets them apart from other second-generation agents such as cefuroxime, which covers Haemophilus influenzae and Moraxella catarrhalis for respiratory infections but lacks meaningful anaerobic activity. Cephamycins are used for intra-abdominal and gynecologic infections where anaerobic coverage is required. They do not cover Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus, and they are not active against extended-spectrum beta-lactamase producers.

Correct Answer

D — Ceftriaxone covalently inactivates penicillin-binding proteins, blocking peptidoglycan cross-linking; meningeal inflammation allows adequate cerebrospinal fluid penetration to achieve bactericidal concentrations

Rationale

Ceftriaxone kills susceptible bacteria by the shared beta-lactam mechanism: covalent binding to and inactivation of penicillin-binding protein transpeptidases, which blocks the final cross-linking step of peptidoglycan synthesis. As cell wall construction fails while autolytic enzymes continue to degrade existing peptidoglycan, the organism undergoes progressive structural failure and bactericidal lysis. Ceftriaxone reaches adequate cerebrospinal fluid concentrations for pneumococcal meningitis because meningeal inflammation increases blood-brain barrier permeability. Its long half-life and once-daily dosing make it the standard of care for bacterial meningitis caused by susceptible organisms. All beta-lactams share this mechanism; the other options describe mechanisms of rifampin, polymyxins, and aminoglycosides respectively.

Correct Answer

B — Cefazolin's 7-position side chain is structurally unrelated to amoxicillin's side chain, conferring the lowest cross-reactivity risk of any cephalosporin in this patient

Rationale

Cross-reactivity between penicillins and cephalosporins is mediated by shared side chain structures, not by the shared beta-lactam ring. This patient's allergy was triggered by amoxicillin. Cephalosporins that share a structural side chain with amoxicillin — such as cefadroxil and cefprozil — carry elevated cross-reactivity risk for this patient and should be avoided. Cefazolin's 7-position side chain is structurally unrelated to any penicillin side chain, making it the cephalosporin with the lowest cross-reactivity risk overall and the standard choice for surgical prophylaxis in most penicillin-allergic patients after appropriate risk stratification. Cefazolin is a first-generation cephalosporin, not second-generation, and is not a beta-lactamase inhibitor combination.

Correct Answer

C — Cephamycins add anaerobic coverage including Bacteroides fragilis, which other second-generation cephalosporins lack

Rationale

Cephamycins — cefoxitin and cefotetan — are second-generation cephalosporins with a distinguishing property: anaerobic coverage that includes Bacteroides fragilis. This property is absent in other second-generation agents such as cefuroxime, which provides enhanced gram-negative coverage for respiratory pathogens but lacks meaningful anaerobic activity. Polymicrobial abdominal infections involving fecal flora require anaerobic coverage as a cornerstone of treatment, making cephamycins the appropriate second-generation choice when anaerobic organisms are present or expected. Cefotetan does not cover Pseudomonas aeruginosa, and its dosing interval is not the basis for selection here.

Correct Answer

A — Ceftaroline has sufficient affinity for the altered penicillin-binding protein in methicillin-resistant Staphylococcus aureus to inactivate it, while other cephalosporins cannot bind this protein at therapeutically achievable concentrations

Rationale

Methicillin-resistant Staphylococcus aureus is resistant to all conventional beta-lactams because it carries an altered penicillin-binding protein with extremely low affinity for the entire drug class. Ceftaroline is the only approved beta-lactam that can overcome this barrier — it is engineered with a side chain that achieves sufficient binding affinity to inactivate the altered penicillin-binding protein and block cell wall synthesis even in methicillin-resistant Staphylococcus aureus. No inhibitor partner is required; the activity is an intrinsic property of ceftaroline's structure. Gene suppression and membrane disruption are not its mechanism.